$RPTX
Repare Therapeutics Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040024 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.670M $1.030M
YoY Change 256.31%
% of Gross Profit
Research & Development $8.951M $4.853M
YoY Change 84.44%
% of Gross Profit
Depreciation & Amortization $200.0K $140.0K
YoY Change 42.86%
% of Gross Profit
Operating Expenses $12.32M $5.885M
YoY Change 109.4%
Operating Profit -$12.32M -$5.885M
YoY Change 109.4%
Interest Expense $600.0K -$450.0K
YoY Change -233.33%
% of Operating Profit
Other Income/Expense, Net $591.0K -$454.0K
YoY Change -230.18%
Pretax Income -$11.73M -$6.339M
YoY Change 85.08%
Income Tax $70.00K $20.00K
% Of Pretax Income
Net Earnings -$11.80M -$6.360M
YoY Change 85.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$321.1K -$181.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $369.9M
YoY Change
Cash & Equivalents $370.1M $28.79M
Short-Term Investments
Other Short-Term Assets $3.300M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $377.3M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.453M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $894.0K
YoY Change
Total Long-Term Assets $4.467M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $377.3M
Total Long-Term Assets $4.467M
Total Assets $381.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.576M
YoY Change
Accrued Expenses $4.200M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.797M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $58.30M
YoY Change
Total Long-Term Liabilities $58.30M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.797M
Total Long-Term Liabilities $58.30M
Total Liabilities $68.08M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$74.34M
YoY Change
Common Stock $388.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $313.7M -$33.40M
YoY Change
Total Liabilities & Shareholders Equity $381.7M
YoY Change

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$11.80M -$6.360M
YoY Change 85.53%
Depreciation, Depletion And Amortization $200.0K $140.0K
YoY Change 42.86%
Cash From Operating Activities $36.69M -$6.080M
YoY Change -703.45%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$300.0K
YoY Change -96.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$300.0K
YoY Change -96.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 249.0M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 36.69M -6.080M
Cash From Investing Activities -10.00K -300.0K
Cash From Financing Activities 249.0M 0.000
Net Change In Cash 285.7M -6.380M
YoY Change -4578.21%
FREE CASH FLOW
Cash From Operating Activities $36.69M -$6.080M
Capital Expenditures -$10.00K -$300.0K
Free Cash Flow $36.70M -$5.780M
YoY Change -734.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash
Cash
94797000
CY2020Q2 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1414000
CY2019Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1080000
CY2020Q2 us-gaap Other Receivables
OtherReceivables
2621000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3296000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
719000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
377264000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
98572000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2453000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2390000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
199000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
208000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
729000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
894000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
359000
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
192000
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
132000
CY2020Q2 us-gaap Assets
Assets
381731000
CY2019Q4 us-gaap Assets
Assets
102695000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3576000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2127000
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5262000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1276000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
608000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
625000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2020Q2 us-gaap Liabilities
Liabilities
68075000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
135997000
CY2020Q2 us-gaap Cash
Cash
369933000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
1976000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1034000
CY2020Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
351000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9797000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136000
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
58142000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8142000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
383818000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4182000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74344000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1528374
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5885000
us-gaap Operating Expenses
OperatingExpenses
23138000
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
us-gaap Operating Expenses
OperatingExpenses
10664000
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
218000
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4246000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
439000
CY2019Q4 us-gaap Liabilities
Liabilities
12827000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1528374
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4853000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17583000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8556000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1032000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5555000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2108000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5885000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23138000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1136000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
299000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
227000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-404000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11068000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
129000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-11197000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11197000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.33
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1528374
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10664000
CY2020Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
313656000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381731000
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36753454
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36753454
CY2020Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
rptx Preferred Stock Authorized Unlimited
PreferredStockAuthorizedUnlimited
Unlimited
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8951000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3372000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
12323000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12323000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
595000
CY2019Q2 rptx Change In Fair Value Of Preferred Share Tranche Obligation
ChangeInFairValueOfPreferredShareTrancheObligation
680000
rptx Change In Fair Value Of Preferred Share Tranche Obligation
ChangeInFairValueOfPreferredShareTrancheObligation
700000
CY2019Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
591000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-454000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1142000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11732000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6339000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24280000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
70000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123000
CY2020Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-11802000
CY2019Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-6359000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-24403000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11802000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6359000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24403000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.56
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4825214
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1528374
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3229635
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-22384000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65000
CY2019Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-4838000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-27157000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-33395000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2020Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-12601000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58135000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
389000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
135997000
CY2020Q2 rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
CY2019Q2 us-gaap Cash
Cash
28588000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
199000
us-gaap Profit Loss
ProfitLoss
-24403000
us-gaap Profit Loss
ProfitLoss
-11197000
us-gaap Share Based Compensation
ShareBasedCompensation
660000
us-gaap Share Based Compensation
ShareBasedCompensation
186000
us-gaap Depreciation
Depreciation
403000
us-gaap Depreciation
Depreciation
262000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
305000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
86000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-1162000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
522000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2577000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
381000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
246000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
725000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
566000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
60000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
42000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
535000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
915000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
260000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2371000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-119000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-9000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
15000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
133000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
72000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-292000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-93000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
50000000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
26967000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3232000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
380000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-380000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
20995000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
488000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
15000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
233760000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
249248000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20995000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1045000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
482000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
275127000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17865000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95005000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10929000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
370132000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28794000
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
206000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
370132000
rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
289000
CY2020Q2 rptx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfStockOptions
10.30
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28794000
rptx Property And Equipment Purchases In Accounts Payable
PropertyAndEquipmentPurchasesInAccountsPayable
423000
rptx Property And Equipment Purchases In Accounts Payable
PropertyAndEquipmentPurchasesInAccountsPayable
14000
rptx Initial Public Offering Costs In Accounts Payable
InitialPublicOfferingCostsInAccountsPayable
102000
rptx Initial Public Offering Costs In Accruals And Other Current Liabilities
InitialPublicOfferingCostsInAccrualsAndOtherCurrentLiabilities
1615000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
135997000
rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued research and development expenses and share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6.062
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.16496
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1118000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1043000
CY2020Q2 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1814000
CY2019Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
208000
CY2020Q2 rptx Accrued Initial Public Offering Costs
AccruedInitialPublicOfferingCosts
1615000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
668000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
21000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
47000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4000
CY2020Q2 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5262000
CY2019Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
1276000
rptx Number Of Operating Leases
NumberOfOperatingLeases
3
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
165000
us-gaap Operating Lease Cost
OperatingLeaseCost
330000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
39000
us-gaap Variable Lease Cost
VariableLeaseCost
92000
CY2020Q2 us-gaap Lease Cost
LeaseCost
205000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.11
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.87
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4099545
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1920950
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.07
us-gaap Lease Cost
LeaseCost
426000
us-gaap Operating Lease Payments
OperatingLeasePayments
335000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M13D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3505119
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
907315
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
869075
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1013635
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
266687
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7962
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.35
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.06
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.13
CY2019Q2 rptx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfStockOptions
0.97
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
16.35
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.06
CY2020Q2 us-gaap Share Price
SharePrice
16.35
CY2019Q2 us-gaap Share Price
SharePrice
2.06
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0227
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7079
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11837000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2020Q2 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-11802000
CY2019Q2 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-6359000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-24403000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-11197000

Files In Submission

Name View Source Status
0001564590-20-040024-index-headers.html Edgar Link pending
0001564590-20-040024-index.html Edgar Link pending
0001564590-20-040024.txt Edgar Link pending
0001564590-20-040024-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-10q_20200630.htm Edgar Link pending
rptx-20200630.xml Edgar Link completed
rptx-20200630.xsd Edgar Link pending
rptx-20200630_cal.xml Edgar Link unprocessable
rptx-20200630_def.xml Edgar Link unprocessable
rptx-20200630_lab.xml Edgar Link unprocessable
rptx-20200630_pre.xml Edgar Link unprocessable
rptx-ex101_64.htm Edgar Link pending
rptx-ex311_9.htm Edgar Link pending
rptx-ex312_8.htm Edgar Link pending
rptx-ex321_7.htm Edgar Link pending
rptx-ex322_6.htm Edgar Link pending
Show.js Edgar Link pending